A government panel on Wednesday approved coverage of a new therapy to treat leukemia and other hematologic cancers, which currently costs 33.49 million yen ($305,000), by national health insurance, a move that would significantly ease the burden on patients.The drug Kymriah, to be produced and sold by Novartis Pharma K.K., a Tokyo-based unit of Swiss pharmaceutical giant Novartis AG, will carry the highest price tag of any single drug in Japan. Coverage is set to take effect May 22.But the decision by the health ministry panel may raise concerns about the impact on the country's ballooning …READ FULL ARTICLE